Towards a roadmap in brain protection and recovery

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 12, 2012, Pages 2861-2871

  Muresanu, Dafin F ^a   Buzoianu, Anca ^a   Florian, Stefan I ^a   von Wild, Tobias ^b  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Damage mechanism; Endogenous defence activity; Multimodal drugs; Neuroprotection; Neurorecovery

Indexed keywords

NEUROPROTECTIVE AGENT;

APOPTOSIS; ARTICLE; BRAIN; BRAIN DISEASE; DRUG EFFECT; HUMAN; INFLAMMATION; NECROSIS; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROLOGIC DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

APOPTOSIS; BRAIN; BRAIN DISEASES; HUMANS; INFLAMMATION; NECROSIS; NERVOUS SYSTEM DISEASES; NEUROGENESIS; NEURONAL PLASTICITY; NEUROPROTECTIVE AGENTS; TREATMENT OUTCOME;

EID: 84871140946     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2012.01605.x     Document Type: Article

References (36)

1. Muresanu DF. Neuroprotection and neuroplasticity-a holistic approach and future perspectives. J Neurol Sci. 2007; 257: 38-43.
2. Ahn AC, Tewari M, Poon C-S, et al. The limits of reductionism in medicine: could systems biology offer an alternative? PLoS Med. 2006; 3: 709-13.
3. Labiche LA, Grotta JC. Clinical trials for cytoprotection in stroke. NeuroRx. 2004; 1: 46-70.
4. Maas AI, Roozenbeek B, Manley GT. Clinical trials in traumatic brain injury: past experience and current developments. Neurotherapeutics. 2010; 7: 115-26.
5. Pocock SJ. Clinical Trials-A Practical Approach. Chichester, New York, Brisbane, Toronto, Singapore: John Wiley & Sons; 1983. p. 265 S.
6. Friedman M, Furberg CD, DeMets L. Fundamentals of Clinical Trials. 3rd ed. New York: Springer-Verlag; 1998. p. 361.
7. Rothwell P. Treating Individuals-From Randomised Trials to Personalised Medicine. London: Elsevier Health Sciences; 2007.
8. Sloviter R. Apoptosis: a guide for perplexed. Trends Pharmacol Sci. 2002; 23: 19-24.
9. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005; 57: 173-85.
10. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol. 2001; 13: 555-62.
11. DeGracia DJ. Towards a dynamical network view of brain ischemia and reperfusion. Part I: background and preliminaries. J Exp Stroke Transl Med. 2010; 3: 59-71.
12. Iseda T, Nishio T, Kawaguchi S, et al. Spontaneous regeneration of the corticospinal tract after transection inyoung rats: a key role of reactive astrocytes in making favourable andunfavourable conditions for regeneration. Neuroscience. 2004; 126: 365-74.
13. Kalivas PW, Volkow ND. The neural basis of addiction: pathology of motivation and choice. Am J Psychiatry. 2005; 162: 1403-13.
14. Muresanu DF. Neurotrophic Factors. Bucuresti: Libripress; 2003.
15. Wu HY, Yuen EY, Lu YF, et al. Regulation of N-Methyl-D-aspartate receptors by calpain in cortical neurons. J Biol Chem. 2005; 280: 21588-93.
16. Hutter-Paier B, Grygar E, Fruhwirth M, et al. Further evidence that Cerebrolysin protects cortical neurons from neurodegeneration in vitro. J Neural Transm Suppl. 1998; 53: 363-72.
17. Hetman M, Kharebava G. Survival signaling pathways activated by NMDA receptors. Curr Top Med Chem. 2006; 6: 787-99.
18. Hardingham GE, Arnold FJ, Bading H. A calcium microdomain near NMDA receptors: on switch for ERK-dependent synapse-tonucleus communication. Nat Neurosci. 2001; 4: 565-6.
19. Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci. 2002; 5: 405-14.
20. Arundine M, Tymianski M. Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. Cell Mol Life Sci. 2004; 61: 657-68.
21. Bano D, Young KW, Guerin CJ, et al. Calpain cleavage of the plasma membrane Na+/Ca2+ exchanger in excitotoxicity. Cell. 2005; 120: 275-85.
22. Stout AK, Raphael HM, Kanterewicz BI, et al. Glutamate-induced neuron death requires mitochondrial calcium uptake. Nat Neurosci. 1998; 1: 366-73.
23. Soriano FX, Hardingham GE. Compartmentalized NMDA receptor signalling to survival and death. J Physiol. 2007; 584-2: 381-7.
24. Iseda T, Nishio T, Kawaguchi S, et al. Spontaneous regeneration of the corticospinal tract after transection in young rats: a key role of reactive astrocytes in making favourable and unfavourable conditions for regeneration. Neuroscience. 2004; 126: 365-74.
25. Kotter MR, Setzu A, Sim FJ, et al. Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination. Glia. 2001; 35: 204-12.
26. Masson JL, Jones JJ, Taniike M, et al. Mature oligodendrocytes apoptosis precedes IGF-I production: an oligodendrocyte progenitor accumulation and differentiation during demyelination/remyelination. J Neurosci Res. 2000; 61: 251-62.
27. Arnett HA, Wang Y, Matsushima GK, et al. Functional genomic analysis of remyelination reveals importance of infl ammation in oligodendrocytes regeneration. J Neurosci. 2003; 23: 9824-32.
28. Marchetti L, Klein M, Schlett K, et al. Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyld-aspartate receptor activation. J Biol Chem. 2004; 279: 32869-81.
29. Becher B, Antel JP. Comparison of phenotypic and functional properties of immediately ex vivo and cultured human adult microglia. Glia. 1996; 18: 1-10.
30. Windhangen A, Newcombe J, Dan-Gond F, et al. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med. 1995; 182: 1985-96.
31. Pachter JS, de Vries HE, Fabry Z. The blood-brain barrier and its role in immune privilege in the central nervous system. J Neuropathol Exp Neurol. 2003; 62: 593-604.
32. Xiao G, Wei J, Yan W, et al. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit Care. 2008; 12: R61.
33. Barnes MP, Dobkin BH, Bogousslavsky J. Recovery after Stroke. New York: Cambridge University Press; 2003.
34. Read SJ, Parsons AA, Harrison DC, et al. Stroke genomics: approaches to identify, validate, and understand ischemic stroke gene expression. J Cereb Blood Flow Metab. 2001; 21: 755-78.
35. Danton GH, Dietrich WD. Inflammatory mechanisms after ischemia and stroke. J Neuropathol Exp Neurol. 2003; 62: 127-36.
36. Ginsberg MD. Injury mechanisms in the ischemic penumbra. Approaches to neuroprotection in acute ischemic stroke. Cerebrovasc Dis. 1997; 7: 7-12.